Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets

References

• Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet. 2021;397(10286):1750–1769.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009;6(12):718–730.
   PubMed Web of Science ®Google Scholar
• Geyer FC, Pareja F, Weigelt B, et al. The spectrum of triple-negative breast disease: high- and low-grade lesions. Am J Pathol. 2017;187(10):2139–2151.
   PubMed Web of Science ®Google Scholar
• Laé M, Fréneaux P, Sastre-Garau X, et al. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol: an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(2):291–298.
   PubMed Web of Science ®Google Scholar
• Persson M, Andrén Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci. 2009;106(44): 18740 LP – 18744.
   Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368.
   PubMed Web of Science ®Google Scholar
• Elsawaf Z, Sinn H-P, Rom J, et al. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast. 2013;22(5):986–992.
   PubMedGoogle Scholar
• Liu Y-R, Jiang Y-Z, X-E X, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18(1):33.
   PubMedGoogle Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418): 61–70.
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–399.
   PubMed Web of Science ®Google Scholar
• Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010 Dec;7(12):683–692.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.
   PubMed Web of Science ®Google Scholar
• Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol: official journal of the European Society for Medical Oncology. 2018;29(4):895–902.
   PubMed Web of Science ®Google Scholar
• Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13(1):188.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhou J, Zhang K, et al. Molecular mechanisms of PALB2 function and its role in breast cancer management. Front Oncol. 2020;10:301.
   PubMedGoogle Scholar
• Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
   PubMed Web of Science ®Google Scholar
• Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628–637.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–1078.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763.
   PubMed Web of Science ®Google Scholar
• Litton JK, Hurvitz SA, Mina LA, et al., Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol: official journal of the European Society for Medical Oncology. 31(11): 1526–1535. 2020.
   PubMed Web of Science ®Google Scholar
• Robson M, S-A I, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566.
   PubMed Web of Science ®Google Scholar
• Robson M, Ruddy KJ, S-A I, et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer. 2019;120:20–30.
   PubMed Web of Science ®Google Scholar
• Tung NM, Robson ME, Ventz S, et al. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). J Clin Oncol. 2020;38(15_suppl):1002.
   Web of Science ®Google Scholar
• Turner NC, Balmaña J, Poncet C, et al. Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. Clin Cancer Res: an official journal of American Association for Cancer Research. 2021;27(20):5482–5491.
   PubMed Web of Science ®Google Scholar
• Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(10):1269–1282.
   PubMed Web of Science ®Google Scholar
• Han HS, Diéras V, Robson M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol: official journal of the European Society for Medical Oncology. 2018;29(1):154–161.
   PubMed Web of Science ®Google Scholar
• Kummar S, Wade JL, Oza AM, et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 Jun;34(3):355–363. DO
   PubMed Web of Science ®Google Scholar
• Yoshida R, Hagio T, Kaneyasu T, et al. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Cancer Sci. 2021 Mar;112(3):1310–1319.
   PubMedGoogle Scholar
• Bono M, Fanale D, Incorvaia L, et al. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. ESMO open. 2021;6(4):100235.
   PubMed Web of Science ®Google Scholar
• Davies H, Glodzik D, Morganella S, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517–525.
   PubMed Web of Science ®Google Scholar
• Staaf J, Glodzik D, Bosch A, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526–1533.
   PubMed Web of Science ®Google Scholar
• Makhale A, Nanayakkara D, Raninga P, et al. CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. Int J Mol Sci. 2021;22(11):5782.
   PubMedGoogle Scholar
• Cruz C, Llop-Guevara A, Garber JE, et al. Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy. J Clin Oncol: Official journal of American Society of Clinical Oncology. 2018;36(31):3134–3143.
   PubMedGoogle Scholar
• Zatreanu D, Robinson HMR, Alkhatib O, et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021;12(1):3636.
   PubMedGoogle Scholar
• Ceccaldi R, Liu JC, Amunugama R, et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature. 2015;518(7538):258–262.
   PubMed Web of Science ®Google Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405.
   PubMed Web of Science ®Google Scholar
• Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512(7513):155–160.
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Ye X, Meeker A, et al. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44(10):2055–2063.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol:official journal of the European Society for Medical Oncology. 2021;32(10):1236–1244.
   PubMedGoogle Scholar
• Mittendorf EA, V PA, Meric-Bernstam F, et al. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res. 2014;2(4): 361 LP – 370.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405–411.
   PubMed Web of Science ®Google Scholar
• Bian L, Zhang H, Wang T, et al. JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. Ann Transl Med. 2019 Sep;7(18):435.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671–686.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib keynote-012 study. J Clin Oncol. 2016;34(21):2460–2467.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928.
   PubMed Web of Science ®Google Scholar
• Huo X, Shen G, Liu Z, et al. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;168:103530.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59.
   PubMed Web of Science ®Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495.
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol: official journal of the European Society for Medical Oncology. 2021;32(8):994–1004.
   PubMed Web of Science ®Google Scholar
• Gradishar W, Moran M, Abraham J. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):484–493.
   PubMedGoogle Scholar
• Kyalwazi B, Yau C, Olopade O. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial. San Antonio Breast Cancer Symp 7-10 December 2021, San Antonio, TX. Abstract GS4-02. 2021.
   Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(15_suppl):1000.
   Google Scholar
• Hutchinson KE, Yost SE, Chang C-W, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin cancer Res: an official journal of the American Association for Cancer Research. 2020;26(3):657–668.
   PubMedGoogle Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tri. Lancet. 2020;396(10257):1090–1100.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684.
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288.
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang C-S, Egle D, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. AACR; 2020.
   Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567.
   PubMed Web of Science ®Google Scholar
• FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer. [cited 2022 May 15]. 2021. https://www.fda.gov/drugs/resources-information-approved-drugs.
   Google Scholar
• Lipinski M, Parks DR, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5147–5150.
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015 Mar;6(3–4):84–105.
   PubMedGoogle Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr;384(16):1529–1541.
   PubMed Web of Science ®Google Scholar
• Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol: official journal of the European Society for Medical Oncology. 2021 Sep;32(9):1148–1156.
   PubMed Web of Science ®Google Scholar
• Santi DV, Cabel L, Bidard F-C. Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?. Ann Transl Med. 2021;9(14):1113.
   PubMedGoogle Scholar
• Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct;123(19):3843–3854.
   PubMed Web of Science ®Google Scholar
• Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701.
   PubMed Web of Science ®Google Scholar
• Eiger D, Agostinetto E, Saúde-Conde R, et al. The exciting new field of HER2-low breast cancer treatment. Cancers (Basel). 2021 Mar 1;13(5):1015.
   Google Scholar
• Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20(12):2329–2340.
   PubMed Web of Science ®Google Scholar
• Caruso, C. TROP2 ADC Intrigues in NSCLC. United States: Cancer discovery; 2021. Vol. 11. p. OF5.
   Google Scholar
• McGuinness JE, Kalinsky K. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opin Biol Ther. 2021 Jul;21(7):903–913.
   PubMed Web of Science ®Google Scholar
• Kogawa T, Yonemori K, Masuda N, et al. Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. J Clin Oncol. 2018;36(15_suppl):2512.
   Google Scholar
• Yao H-P, Zhao H, Hudson R, et al. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today. 2021;26(8):1857–1874.
   PubMed Web of Science ®Google Scholar
• Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135.
   PubMed Web of Science ®Google Scholar
• Lim B, Seth S, Huo L, et al. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. J Clin Oncol. 2020;38(15_suppl):517.
   Google Scholar
• Traina TA, Boyle LA, Arumov A, et al. Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC. J Clin Oncol. 2019;37(15_suppl):546.
   Google Scholar
• Traina TA, Jones LW, Blinder V, et al. Abstract P5-12-09: Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. Cancer Res. 2020;80(4 Supplement): 5-12-09 LP-P5-12–09. DOI:https://doi.org/10.1158/0008-5472.CAN-19-1169
   Google Scholar
• Vetter MHF, Rothgiesser K, Li Q, et al. SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer. Ann Oncol. 2019;30:iii52.
   Google Scholar
• Yuan Y, Lee JS, Yost SE, et al. A Phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist. 2021;26(2):99–e217.
   PubMedGoogle Scholar
• Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 2016;7(29):46482–46491.
   PubMedGoogle Scholar
• Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Vol. 68. Cancer Treatment Reviews. W.B. Saunders Ltd; 2018. p. 102–110.
   Google Scholar
• Maeda T, Nakanishi Y, Hirotani Y, et al. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol. 2016;49(1):11–21.
   PubMed Web of Science ®Google Scholar
• Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One. 2014;9(2):e88525.
   PubMed Web of Science ®Google Scholar
• McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. Cancer Sci. 2013;104(5):639–646.
   PubMedGoogle Scholar
• Loibl S, Müller BM, von Minckwitz G, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;130(2):477–487.
   PubMed Web of Science ®Google Scholar
• Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19): 5533 LP – 5540. DOI:https://doi.org/10.1158/1078-0432.CCR-13-0799
   Google Scholar
• Agostinetto E, Eiger D, Punie K, et al. Emerging therapeutics for patients with triple-negative breast cancer. Curr Oncol Rep. 2021;23(5):57.
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–1698.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin cancer Res: an official journal of Am Association for Cancer Research. 2013;19(19):5505–5512.
   PubMed Web of Science ®Google Scholar
• Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884–890.
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812–818.
   PubMed Web of Science ®Google Scholar
• Dent R, Schmid P, Cortes J, et al. Abstract OT3-02-02: ENDEAR: a randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer. Cancer Res. 2017:OT3–02.
   Google Scholar
• Patel JM, Goss A, Garber JE, et al. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. npj Breast Cancer. 2020;6(1):19.
   PubMedGoogle Scholar
• Gucalp A, Boyle LA, Alano T, et al. Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. J Clin Oncol. 2020;38(15_suppl):1017.
   Web of Science ®Google Scholar
• Lehmann BD, Abramson VG, Sanders ME, et al. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer. Clin cancer Res: an official journal of American Association for Cancer Research. 2020;26(9):2111–2123.
   PubMed Web of Science ®Google Scholar
• Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397–406.
   PubMed Web of Science ®Google Scholar
• Cossu-Rocca P, Orrù S, Muroni MR, et al. Analysis of PIK3CA mutations and activation pathways in triple negative breast cancer. PLoS One. 2015;10(11):e0141763.
   PubMed Web of Science ®Google Scholar
• Lee C, Kim J-S, Waldman T. Activated PI3K signaling as an endogenous inducer of p53 in human cancer. Cell Cycle. 2007;6(4):394–396.
   PubMed Web of Science ®Google Scholar
• Sharma P, Abramson VG, O’Dea A, et al. Clinical and biomarker results from Phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer. Clin cancer Res: an official journal of American Association for Cancer Research. 2021;27(14):3896–3904.
   PubMed Web of Science ®Google Scholar
• Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol: official journal of American Society of Clinical Oncology. 2020;38(5):423–433.
   PubMed Web of Science ®Google Scholar
• Dent R, Oliveira M, Isakoff SJ, et al. 139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31:S64–5.
   Google Scholar
• Kim S-B, Dent R, S-A I, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18(10):1360–1372.
   PubMed Web of Science ®Google Scholar
• Dent R, Kim S-B, Oliveira M, et al. Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cance. Cancer Res. 2021;81(4 Supplement): GS3-04 LP-GS3-04.
   Google Scholar
• Oliveira M, Saura C, Nuciforo P, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30(8):1289–1297.
   PubMed Web of Science ®Google Scholar
• Damodaran S, Litton JK, Hess KR, et al. Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations. Cancer Res. 2020 Feb 15;80(4 Supplement): OT2-06-01 LP-OT2-06–01.
   Google Scholar
• Giltnane JM, Balko JM. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med. 2014;17(95):275–283.
   PubMed Web of Science ®Google Scholar
• Tilch E, Seidens T, Cocciardi S, et al. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Res Treat. 2014;143(2):385–392.
   PubMedGoogle Scholar
• Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008 Dec;8(8):733–740.
   PubMedGoogle Scholar
• Adeyinka A, Nui Y, Cherlet T, et al. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res. 2002 Jun 1;8(6): 1747 LP – 1753.
   Google Scholar
• Adjei AA, LoRusso P, Ribas A, et al. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017;35(1):47–58.
   PubMed Web of Science ®Google Scholar
• Leijen S, Middleton MR, Tresca P, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin cancer Res: an official journal of American Association for Cancer Research. 2012;18(17):4794–4805.
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol: official journal of American Society of Clinical Oncology. 2005;23(23):5281–5293.
   PubMed Web of Science ®Google Scholar
• Schmid P, Forster MD, Summers YJ, et al. A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results. J Clin Oncol. 2017;35(15_suppl):2548.
   Google Scholar
• Ramaswamy B, Mrozek E, Lustberg M, et al. Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer. Cancer Res. 76(14 Supplement): LB-216 LP-LB-216.
   Google Scholar
• Bräutigam K, Kabore-Wolff E, Hussain AF, et al. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines. J Cancer Res Clin Oncol. 2021;147(10):2923–2933.
   PubMedGoogle Scholar
• Beeram M, Wang JS, Mina LA, et al. First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients, PS11-33, SABCS; 2021.
   Google Scholar
• Dawson MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science. 2017;355(6330):1147–1152.
   PubMed Web of Science ®Google Scholar
• Wimalasena VK, Wang T, Sigua LH, et al. Using chemical epigenetics to target cancer. Mol Cell. 2020 Jun;78(6):1086–1095.
   PubMedGoogle Scholar
• Li Y, Zhan Z, Yin X, et al. Targeted therapeutic strategies for triple-negative breast cancer. Front Oncol. 2021;11. DOI:https://doi.org/10.3389/fonc.2021.731535
   Google Scholar
• Jones PA. DNA methylation and cancer. Oncogene. 2002;21(35):5358–5360.
   PubMedGoogle Scholar
• Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564–569.
   PubMedGoogle Scholar
• Shin E, Lee Y, Koo JS. Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology. J Transl Med. 2016;14:87.
   PubMed Web of Science ®Google Scholar
• Muvarak NE, Chowdhury K, Xia L, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell. 2016;30(4):637–650.
   PubMed Web of Science ®Google Scholar
• Catteau A, Harris WH, Xu CF, et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999;18(11):1957–1965.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30–39.
   PubMed Web of Science ®Google Scholar
• Pegoraro S, Ros G, Sgubin M, et al. Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies. Expert Opin Ther Targets. 2020;24(10):953–969.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Pegoraro S, Ros G, et al. High Mobility Group A (HMGA) proteins: Molecular investigators of breast cancer onset and progression. Biochim Biophys acta Rev cancer. 2018;1869(2):216–229.
   PubMedGoogle Scholar